Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | DHPS | P49366 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455970 | 0.91 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL3455310 | 0.85 | RAF1 (0.47) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL3456079 | 0.82 | ADORA2A (0.44) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL5448755 | 0.78 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL3455974 | 0.76 | ADORA2A (0.42) | ADORA2AADORA1ADORA2BADORA3TP53 | |
| SCHEMBL3457100 | 0.76 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL5449809 | 0.75 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL5458678 | 0.75 | ADORA2A (0.47) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL5193491 | 0.71 | TLR8 (0.42) | ADORA2AADORA1ADORA2BMAPK14MAPK13 | |
| SCHEMBL5189572 | 0.70 | MAPK14 (0.46) | ADORA2AADORA1ADORA2BMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | claimed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA2A 539/4885ADORA1 328/4885ADORA2B 307/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 4/4885ADORA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.